RSV Vaccine to Protect Young and Old

Prefusion-stabilized F glycoprotein RSV vaccine reduced incidence of lower respiratory tract illness in infants when given to their mothers during pregnancy, and in older adults.

Respiratory syncytial virus (RSV) infections cause significant morbidity in infants and elders. In two industry-sponsored studies, efficacy of a bivalent prefusion-stabilized F glycoprotein RSV vaccine was evaluated in pregnant women (to prevent disease in their infants) and in older adults.

In the MATISSE study, investigators randomized 7358 pregnant women (median 31.3 weeks' gestation) to receive vaccine or placebo, then performed disease surveillance in their infants for 12–24 months to assess prevention of medically attended severe RSV-associated lower respiratory tract illness (LRTI) and medically attended RSV-associated LRTI in infants within 180 days of birth (the primary endpoints). Vaccine efficacy (VE) at preventing medically atten…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

RSV Vaccine to Protect Young and Old

Topics

Reviewing Author